For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

A federal judge in Massachusetts ruled on Monday that directives from the Trump administration that led to the cancellations ...

The S&P 500 added 0.9% on Monday, June 16, as investors absorbed the possibility of cooling geopolitical tensions and looked ...

Barclays Speaking the Science Call Series Call June 16, 2025 10:00 AM ETCompany ParticipantsLavina Talukdar - Senior VP ...

F or the past 60 years, a committee of independent experts has advised the federal government on vaccine policy, providing ...

COVID-19 appears to be on the rise in some parts of California as a new, highly contagious subvariant — featuring 'razor ...

REGINA, SASKATCHEWAN / ACCESS Newswire / June 16, 2025 / Consumer Choice Award (CCA) is proud to announce that Affordable ...

TRNR is expected to have the largest US publicly listed crypto treasury focused on an AI-token TRNR began acquiring $FET in ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the US Food and Drug Administration (FDA) ...

Planning Underway for Expedited Follow-up RC and Diamond Programs HIGHLIGHTS 2,882m reverse circulation (RC) drilling ...

NEW YORK CITY, NEW YORK / ACCESS Newswire / June 14, 2025 / New to The Street (NTTS) and High Performance Battery Technology ...

The drugmaker plans to ask for FDA approval of the vaccine this year, while other pharmaceutical companies are also working on RSV vaccines. CNBC: Moderna: RSV Vaccine Effective In Preventing Disease ...